Jiangsu Hengrui Medicine Co., Ltd., established in 1970, is a leading Chinese pharmaceutical company with annual net sales of over $1.6 billion in 2016. Hengrui is devoted to empowering healthier lives through innovation, with 5 R&D centers globally in New Jersey/US, Shanghai, Suzhou, Lianyungang, and Chengdu. Hengrui currently has 2 marketed innovative drugs, 3 NDAs under CFDA review as well as 23 new molecular entities in clinical development in China, US, and Australia, across oncology, anesthesiology & pain management, immunology & inflammation, and cardiovascular & metabolic diseases.